HC Wainwright Lowers Earnings Estimates for Coherus Oncology

Coherus Oncology, Inc. (NASDAQ:CHRS) – Investment analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of Coherus Oncology in a research report issued on Thursday, August 6th. HC Wainwright analyst D. Tsao now forecasts that the biotechnology company will post earnings of ($0.23) per share for the quarter, down from their prior estimate of ($0.18). The consensus estimate for Coherus Oncology’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Coherus Oncology’s Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($0.68) EPS, FY2028 earnings at ($0.96) EPS, FY2029 earnings at ($0.79) EPS and FY2030 earnings at $0.12 EPS.

Coherus Oncology (NASDAQ:CHRS) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.06. Coherus Oncology had a negative net margin of 259.41% and a negative return on equity of 222.75%. The business had revenue of $14.31 million for the quarter, compared to analysts’ expectations of $14.41 million.

Other equities analysts have also recently issued research reports about the company. Guggenheim began coverage on Coherus Oncology in a report on Monday, May 11th. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Coherus Oncology in a report on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $8.67.

Coherus Oncology Stock Down 4.2%

NASDAQ CHRS opened at $1.15 on Monday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.70 and a current ratio of 1.77. The company has a market capitalization of $177.68 million, a P/E ratio of -1.12 and a beta of 0.98. Coherus Oncology has a one year low of $1.03 and a one year high of $2.62. The stock has a 50 day moving average price of $1.42 and a 200-day moving average price of $1.63.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CHRS. Quarry LP purchased a new position in Coherus Oncology during the third quarter valued at approximately $26,000. Blair William & Co. IL purchased a new position in Coherus Oncology in the fourth quarter valued at about $27,000. Bronte Capital Management Pty Ltd. purchased a new position in Coherus Oncology in the fourth quarter valued at about $27,000. China Universal Asset Management Co. Ltd. bought a new position in Coherus Oncology in the fourth quarter worth about $28,000. Finally, Kestra Private Wealth Services LLC bought a new position in Coherus Oncology in the fourth quarter worth about $28,000. 72.82% of the stock is currently owned by institutional investors.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.